Your browser doesn't support javascript.
loading
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
Kim, Gi-Ae; Jeong, Seogsong; Jang, Heejoon; Lee, Dong Hyeon; Joo, Sae Kyung; Kim, Won.
Afiliación
  • Kim GA; Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea.
  • Jeong S; Department of Medical Informatics, College of Medicine, Korea University, Seoul, Republic of Korea.
  • Jang H; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Lee DH; Divisions of Gastroenterology and Hepatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea.
  • Joo SK; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Kim W; Divisions of Gastroenterology and Hepatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea.
Liver Cancer ; 13(4): 426-437, 2024 Aug.
Article en En | MEDLINE | ID: mdl-39114758
ABSTRACT

Introduction:

This study aimed to investigate the liver-related outcomes of newly suggested metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD), as well as alcohol-associated liver disease (ALD).

Methods:

From a National Health Insurance Service Health Screening Cohort, we included 369,094 participants who underwent health checkups between 2009 and 2010 in South Korea. Steatotic liver disease (SLD) was defined as a fatty liver index ≥60. The risk of primary liver cancer (PLCa), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), incident cirrhosis, and decompensated cirrhosis was compared with no SLD. The subdistribution hazard ratio (SHR) was calculated using the Fine-Gray model regarding competing risks.

Results:

A total of 3,232 participants (0.9%) developed PLCa during the median follow-up of 3,227,176 person-years 0.5% with no SLD, 1.1% with MASLD, 1.3% with MetALD, and 1.9% with ALD. Competing risk analysis revealed that compared with no SLD, MASLD (SHR 1.65; 95% CI 1.44-1.88), MetALD (SHR 1.87; 95% CI 1.52-2.29), and ALD (SHR 1.86; 95% CI 1.39-2.49) were associated with an increased risk of PLCa. MASLD (SHR 1.96; 95% CI 1.67-2.31), MetALD (SHR 2.23; 95% CI 1.75-2.84), and ALD (SHR 2.34; 95% CI 1.67-3.29) were associated with a higher risk of HCC. No significant difference was observed in the risk of iCCA. The risk of incident cirrhosis and decompensated cirrhosis increased in the order of no SLD, MASLD, MetALD, and ALD.

Conclusion:

MASLD, MetALD, and ALD have an increased risk of PLCa, HCC, incident cirrhosis, and decompensated cirrhosis but not iCCA. These findings may serve as a robust ground for the prognostic value of the newly suggested MASLD and MetALD.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Liver Cancer Año: 2024 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Liver Cancer Año: 2024 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Suiza